Filing Flows › Agios Pharmaceuticals (AGIO) › Q2 2026
Agios Pharmaceuticals (AGIO) Q2 2026 earnings results (second quarter 2026)
10-Q filed Jul 30, 2026
Agios Pharmaceuticals (AGIO) reported revenue of $44.7M for the second quarter 2026 (Q2 2026), +259% from a year earlier and +116% from the quarter before. Operating margin was -247.1%, net loss $101M (225.1% of revenue).
Agios Pharmaceuticals, Q2 2026: revenue $44.7M (+259% year over year), operating margin -247.1%, net loss $101M, operating cash flow −$57.3M. The chart follows the revenue to costs, profit and cash.
| Q2 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $44.7M | +116% | +259% |
| Operating profit | −$111M | — | — |
| Net earnings | −$101M | — | — |
| Operating cash flow | −$57.3M | — | — |
What changed
Revenue was $44.7M in Q2 2026, up 259% year over year and up 116% from the previous quarter.
Operating costs exceeded revenue by $110.6M, an operating margin of -247.1%. Total costs grew 11% against revenue growth of 259%. The fastest-growing cost line was Cost of revenue (+76%). The quarter ended with a net loss of $100.7M, wider than the previous quarter's $99.1M loss.
Operating cash flow was −$57.3M. Non-cash charges added back $15.9M of share-based compensation. Working capital and other items added $27.4M. Capital expenditures of $1.2M exceeded it, leaving free cash flow of −$58.5M.
Questions
What was Agios Pharmaceuticals' revenue in the second quarter 2026?
Agios Pharmaceuticals (AGIO) reported revenue of $44.7M for the second quarter 2026 (Q2 2026), +259% from a year earlier and +116% from the quarter before.
Was Agios Pharmaceuticals profitable in the second quarter 2026?
Operating loss was $111M (-247.1% of revenue) and net loss $101M.